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costeroids and cyclosporine A, and one patient with corti-
costeroids. We speculated that one patient with leukemia
at 11 months after cyclophosphamide treatment might
be related to the immunosuppressive therapy because
leukemia is well known as one of the early complica-
tions of cyclophosphamide therapy. It is also reported
that cyclosporine is related to malignant lymphoma, es-
pecially MALT lymphoma, but patients with cyclosporine
in our study didn’t develop lymphoma. In the cohort
study of Wegener’s granulomatosis treated by corticos-
teroids and cyclophosphamide in Sweden, Knight re-
ported that there was a 2-fold overall increased risk for
cancer. The increase was most pronounced for bladder
cancer (SIR = 4.8; 95% CI 2.6–8.1), squamous cell skin
cancer (SIR = 7.3; 95% CI 4.4–12), leukemia (SIR = 5.3;
95% CI 2.2–12) and for malignant lymphomas (SIR = 4.2;
95% CI 4.2–8.3) [2]. Hence, we should consider the risk
for cancer in the cases of long-term immunosuppressive
therapy.
Electron-dense deposits in glomerular lesions of ma-
lignancy showed various patterns (data not shown) as
in our previous report about hepatitis B virus–related
glomerulonephritis including hepatocellular carcinoma
[3]. In contrast, electron-dense deposits were identi-
fied only at subepithelial or intramembranous regions in
these seven patients. We judged these cases as idiopathic
membranous nephropathy in pathologic aspect. There
was statistically no significant difference in pathologic
findings at initial biopsies between the seven malignant
patients and those without malignancy. However, the
deep subgroup (two patients out of seven patients, 28.5%)
or heterogeneous type (4 patients out of 45 patients,
8.9%) tended to develop neoplasm during their clinical
course compared with those of homogeneous type with-
out deep subgroup (one patient out of 53 patients, 1.9%).
We need to further investigate the relation between the
electron-dense deposition pattern, especially deep sub-
group and malignancy.
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Plasma activin A in
hemodialysis patients: Does
brand of immunoassay matter?
To the Editor: Activin A is a newly recognized pluripo-
tent growth factor [1]. In a recent issue of Kidney Interna-
tional, we reported for the first time on plasma levels of
immunoreactive activin A in patients undergoing main-
tenance hemodialysis [2]. Predialysis levels were 143 ±
81.7 pg/mL in 25 patients, and not different from those
of 111 ± 67.1 pg/mL in 18 healthy subjects when mea-
sured with commercial colorimetric immunoenzymatic
assay kits from R&D Systems, Inc. (Quantikine; cat.
no. DAC00; Minneapolis, MN, USA). Presently, we de-
termined plasma activin A in another group of 35 chronic
hemodialysis patients using immunoenzymatic kits pur-
chased from Oxford Bio-Innovation, Ltd. (product code:
MCA1426KZZ; Oxfordshire, UK) [3]. Surprisingly, they
were a median of 978 (range 559 to 2560) pg/mL, and
more than 3-fold increased compared with those in 30
healthy control subjects (286 ± 127 pg/mL). The direct
comparison of the two immunoassays for activin A, yield-
ing such disparate results, was not possible because R&D
Systems had discontinued manufacturing the kit. At the
same time, serum activin A level measured recently
in healthy subjects by radioimmunoassay from Serotec
Limited (Oxford, UK) was about 400 pg/mL [4]. This re-
sult is closer to our present rather than our previous [2]
findings in healthy control subjects.
The issue whether predialysis plasma activin A level
in hemodialysis patients is actually normal or increased
remains thus unresolved. It deserves further studies em-
ploying standardized methods.
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